November 2, 2021
Life Sciences
  • Pfizer said its COVID-19 vaccine brought in $13 billion in sales in the third quarter and boosted its year-end forecast to $36 billion due to global deals for booster shots and broader eligibility for the vaccine. The company said it plans to deliver 2.3 billion doses in 2021, out of the roughly 3 billion shots it will manufacture. (Article here)